Elevated phospholipids and acylcarnitines C4 and C5 in cerebrospinal fluid distinguish viral CNS infections from autoimmune neuroinflammation.
Autoimmunity
Biomarkers
Cell membrane
Central nervous system
Encephalitis
Enterovirus
Fatty acid oxidation
Glycerophospholipids
Herpes simplex virus
Infection
Isobutyrylcarnitine
Isovalerylcarnitine
Lecithin
Lysophosphatidylcholine
Meningitis
Metabolism
Mitochondria
Phosphatidylcholine
Phospholipid
Sphingomyelin
Varicella zoster virus
n-methyl-D-aspartate receptor
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
02 11 2023
02 11 2023
Historique:
received:
31
08
2023
accepted:
16
10
2023
medline:
6
11
2023
pubmed:
3
11
2023
entrez:
3
11
2023
Statut:
epublish
Résumé
Viral and autoimmune encephalitis may present with similar symptoms, but require different treatments. Thus, there is a need for biomarkers to improve diagnosis and understanding of pathogenesis. We hypothesized that virus-host cell interactions lead to different changes in central nervous system (CNS) metabolism than autoimmune processes and searched for metabolite biomarkers in cerebrospinal fluid (CSF) to distinguish between the two conditions. We applied a targeted metabolomic/lipidomic analysis to CSF samples from patients with viral CNS infections (n = 34; due to herpes simplex virus [n = 9], varicella zoster virus [n = 15], enteroviruses [n = 10]), autoimmune neuroinflammation (n = 25; autoimmune anti-NMDA-receptor encephalitis [n = 8], multiple sclerosis [n = 17), and non-inflamed controls (n = 31; Gilles de la Tourette syndrome [n = 20], Bell's palsy with normal CSF cell count [n = 11]). 85 metabolites passed quality screening and were evaluated as biomarkers. Standard diagnostic CSF parameters were assessed for comparison. Of the standard CSF parameters, the best biomarkers were: CSF cell count for viral infections vs. controls (area under the ROC curve, AUC = 0.93), Q-albumin for viral infections vs. autoimmune neuroinflammation (AUC = 0.86), and IgG index for autoimmune neuroinflammation vs. controls (AUC = 0.90). Concentrations of 2 metabolites differed significantly (p < 0.05) between autoimmune neuroinflammation and controls, with proline being the best biomarker (AUC = 0.77). In contrast, concentrations of 67 metabolites were significantly higher in viral infections than controls, with SM.C16.0 being the best biomarker (AUC = 0.94). Concentrations of 68 metabolites were significantly higher in viral infections than in autoimmune neuroinflammation, and the 10 most accurate metabolite biomarkers (AUC = 0.89-0.93) were substantially better than Q-albumin (AUC = 0.86). These biomarkers comprised six phosphatidylcholines (AUC = 0.89-0.92), two sphingomyelins (AUC = 0.89, 0.91), and acylcarnitines isobutyrylcarnitine (C4, AUC = 0.92) and isovalerylcarnitine (C5, AUC = 0.93). Elevated C4 and C5 concentrations suggested dysfunctional mitochondrial β-oxidation and correlated only moderately with CSF cell count (Spearman ρ = 0.41 and 0.44), indicating that their increase is not primarily driven by inflammation. Changes in CNS metabolism differ substantially between viral CNS infections and autoimmune neuroinflammation and reveal CSF metabolites as pathophysiologically relevant diagnostic biomarkers for the differentiation between the two conditions. In viral CNS infections, the observed higher concentrations of free phospholipids are consistent with disruption of host cell membranes, whereas the elevated short-chain acylcarnitines likely reflect compromised mitochondrial homeostasis and energy generation.
Sections du résumé
BACKGROUND
Viral and autoimmune encephalitis may present with similar symptoms, but require different treatments. Thus, there is a need for biomarkers to improve diagnosis and understanding of pathogenesis. We hypothesized that virus-host cell interactions lead to different changes in central nervous system (CNS) metabolism than autoimmune processes and searched for metabolite biomarkers in cerebrospinal fluid (CSF) to distinguish between the two conditions.
METHODS
We applied a targeted metabolomic/lipidomic analysis to CSF samples from patients with viral CNS infections (n = 34; due to herpes simplex virus [n = 9], varicella zoster virus [n = 15], enteroviruses [n = 10]), autoimmune neuroinflammation (n = 25; autoimmune anti-NMDA-receptor encephalitis [n = 8], multiple sclerosis [n = 17), and non-inflamed controls (n = 31; Gilles de la Tourette syndrome [n = 20], Bell's palsy with normal CSF cell count [n = 11]). 85 metabolites passed quality screening and were evaluated as biomarkers. Standard diagnostic CSF parameters were assessed for comparison.
RESULTS
Of the standard CSF parameters, the best biomarkers were: CSF cell count for viral infections vs. controls (area under the ROC curve, AUC = 0.93), Q-albumin for viral infections vs. autoimmune neuroinflammation (AUC = 0.86), and IgG index for autoimmune neuroinflammation vs. controls (AUC = 0.90). Concentrations of 2 metabolites differed significantly (p < 0.05) between autoimmune neuroinflammation and controls, with proline being the best biomarker (AUC = 0.77). In contrast, concentrations of 67 metabolites were significantly higher in viral infections than controls, with SM.C16.0 being the best biomarker (AUC = 0.94). Concentrations of 68 metabolites were significantly higher in viral infections than in autoimmune neuroinflammation, and the 10 most accurate metabolite biomarkers (AUC = 0.89-0.93) were substantially better than Q-albumin (AUC = 0.86). These biomarkers comprised six phosphatidylcholines (AUC = 0.89-0.92), two sphingomyelins (AUC = 0.89, 0.91), and acylcarnitines isobutyrylcarnitine (C4, AUC = 0.92) and isovalerylcarnitine (C5, AUC = 0.93). Elevated C4 and C5 concentrations suggested dysfunctional mitochondrial β-oxidation and correlated only moderately with CSF cell count (Spearman ρ = 0.41 and 0.44), indicating that their increase is not primarily driven by inflammation.
CONCLUSIONS
Changes in CNS metabolism differ substantially between viral CNS infections and autoimmune neuroinflammation and reveal CSF metabolites as pathophysiologically relevant diagnostic biomarkers for the differentiation between the two conditions. In viral CNS infections, the observed higher concentrations of free phospholipids are consistent with disruption of host cell membranes, whereas the elevated short-chain acylcarnitines likely reflect compromised mitochondrial homeostasis and energy generation.
Identifiants
pubmed: 37919735
doi: 10.1186/s12967-023-04637-y
pii: 10.1186/s12967-023-04637-y
pmc: PMC10621113
doi:
Substances chimiques
Phospholipids
0
acylcarnitine
0
Biomarkers
0
Albumins
0
Banques de données
figshare
['10.6084/m9.figshare.24321475']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
776Informations de copyright
© 2023. The Author(s).
Références
Sci Rep. 2020 Sep 30;10(1):16173
pubmed: 32999423
Clin Infect Dis. 2023 Feb 8;76(3):e1294-e1301
pubmed: 36053949
Ann Clin Transl Neurol. 2021 Dec;8(12):2228-2234
pubmed: 34623755
Int J Mol Sci. 2019 Jan 15;20(2):
pubmed: 30650575
Front Immunol. 2022 Oct 26;13:971659
pubmed: 36389787
Lancet Neurol. 2018 Sep;17(9):760-772
pubmed: 30049614
J Clin Invest. 2022 Feb 1;132(3):
pubmed: 34847081
J Infect Dis. 2019 Jun 5;220(1):127-138
pubmed: 30721966
BMC Bioinformatics. 2006 Feb 23;7:91
pubmed: 16504092
Lancet Neurol. 2016 Apr;15(4):391-404
pubmed: 26906964
Semin Neurol. 2000;20(3):277-92
pubmed: 11051293
Neurology. 2014 Feb 4;82(5):443-51
pubmed: 24384647
Cytokine. 2016 Jan;77:227-37
pubmed: 26463515
Neurology. 2013 Oct 29;81(18):1637-9
pubmed: 24089390
J Neurovirol. 2016 Oct;22(5):674-682
pubmed: 27245593
Diagnostics (Basel). 2020 Dec 28;11(1):
pubmed: 33379245
Nature. 2015 Nov 19;527(7578):S178-86
pubmed: 26580325
Clin Transl Med. 2022 Jul;12(7):e931
pubmed: 35842904
J Neuroinflammation. 2018 Jan 17;15(1):20
pubmed: 29343258
Pract Neurol. 2021 Oct;21(5):412-423
pubmed: 34108243
Cureus. 2022 Oct 11;14(10):e30186
pubmed: 36397921
N Engl J Med. 2018 Aug 9;379(6):557-566
pubmed: 30089069
Bioinformatics. 2005 Oct 15;21(20):3940-1
pubmed: 16096348
J Transl Med. 2020 Jan 7;18(1):9
pubmed: 31910875
Mult Scler. 1998 Jun;4(3):99-107
pubmed: 9762655
Mitochondrion. 2019 May;46:73-90
pubmed: 29551309
Metabolomics. 2012 Jun;8(Suppl 1):3-16
pubmed: 22593721
Cells. 2021 May 06;10(5):
pubmed: 34066349
mBio. 2021 Dec 21;12(6):e0255721
pubmed: 34809467